# Guadecitabine Extension Study

> **NCT03603964** · PHASE2 · TERMINATED · sponsor: **Astex Pharmaceuticals, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myeloid Dysplastic Syndrome

## Interventions

- **DRUG:** Guadecitabine

## Key facts

- **NCT ID:** NCT03603964
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-18
- **Primary completion:** 2021-10-04
- **Final completion:** 2021-10-04
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Early termination not due to patient safety
- **Last updated:** 2024-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03603964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03603964, "Guadecitabine Extension Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03603964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*